Clinical trials
Phase 3 Tourette Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 4 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Terminated | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 |
| Baylor College of Medicine | 2 |
| Emalex Biosciences Inc. | 2 |
| Teva Branded Pharmaceutical Products R&D, Inc. | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Boehringer Ingelheim | 1 |
| Hannover Medical School | 1 |
| Korea Otsuka Pharmaceutical Co., Ltd. | 1 |
| National Center for Research Resources (NCRR) | 1 |
| Otsuka Beijing Research Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tourette Syndrome | 18 |
| Tic Disorders | 9 |
| Mental Disorders | 4 |
| Brain Diseases | 3 |
| Central Nervous System Diseases | 3 |
| Movement Disorders | 3 |
| Basal Ganglia Diseases | 2 |
| Tics | 2 |
| Nervous System Diseases | 1 |
| Neurodegenerative Diseases | 1 |
Trials
Showing 76 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.